Therapeutic | Bezlotoxumab |
Target | Toxin A |
Heavy Chain | EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS |
Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK |
100% seqID Fv Structure | 4np4 [Fvs: HL, IM] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4np4 [Fvs: HL, IM] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | Medarex HuMAb Mouse |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Medarex, University of Massachusetts Medical School, Merck & Co, Merck Sharp & Dohme |
Conditions Approved | Clostridium difficile |
Conditions Active | na |
Conditions Discontinued | na |
Notes |